Sponsor: Technische Universität Dresden
AML-Register
Dieses Register wendet sich an alle Patienten ab 18 Jahren mit einer akuten myeloischen Leukämie

Sponsor: Technische Universität Dresden
MOSAIC: MidOStaurin + Gemtuzumab OzogAmicin Combination in First-line Standard Therapy for Acute Myeloid Leukemia
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-514014-13-00

Sponsor: Technische Universität Dresden
VINCENT: Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-515267-59-00

Sponsor: Technische Universität Dresden 
RELEVANT / ETAL-5: Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Transplantation (RELEVANT)
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-507879-21-00

APL NAPOLEON-Register

Diese so genannte „akute Promyelozyten-Leukämie (APL)“ ist sehr selten und soll deshalb in einem deutschlandweiten Register erfasst werden, um mehr über die Erkrankung zu erfahren. Es haben sich innerhalb Deutschlands verschiedene Studiengruppen zusammengeschlossen, um die Patientendaten einheitlich zu erfassen und die Therapiemöglichkeiten dadurch weiter zu verbessern. Das Ziel dieser (nicht‐interventionellen, also ohne direkte Vorgaben, wie Ihr Arzt Sie behandeln soll) Beobachtungsstudie ist es, die Befunde zur Diagnostik und Therapie der APL in der täglichen Praxis im Langzeitverlauf zu dokumentieren und auszuwerten. Ihre Behandlung erfolgt dabei ausschließlich nach internationalen Standards und mit in Deutschland zugelassenen Medikamenten. Die Beobachtungsstudie wird außerdem die Lebensqualität der Patienten dokumentieren, um zu lernen, wie diese sich in verschiedenen Patientengruppen unterscheiden.

Dieses Register wendet sich an alle Patienten

• mit einer akuten myeloischen Leukämie (sogenannte M3 oder APL, einer speziellen Variante der AML)

Sponsor: Goethe Universität Frankfurt
ALL-Register
Dieses Register wendet sich an alle Patienten ab 18 Jahren mit einer akuten lymphatischen Leukämie

Sponsor: Goethe Universität Frankfurt
GMALL-EVOLVE: A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent  llogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab before SCT in suboptimal responders
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-517966-40-00

Sponsor: Goethe Universität Frankfurt
GMALL-Isatuximab: A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemia
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-507899-47-00

Sponsor: Universität Köln
CLL-Register
Dieses Register wendet sich an alle Patienten ab 18 Jahren mit einer Chronische Lymphatische Leukämie

Sponsor: Johannes-Gutenberg-Universität Mainz
EMCL Register 
Dieses Register wendet sich an alle Patienten ab 18 Jahren mit einem Mantelzell-Lymphom

Sponsor: German Lymphoma Alliance e.V. (GLA)
GLA Register
Dieses Register wendet sich an alle Patienten ab 18 Jahren mit malignen Lymphomen

Sponsor: Universität Köln
CLL16: A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVe) Compared to Obinutuzumab and Venetoclax (GVe) in Previously Untreated Patients with High Risk (17p-deletion, TP53-mutation or complex karyotype) Chronic Lymphocytic Leukemia (CLL)
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-506414-46-00

Sponsor: Universität Köln
CLL18: Sponsor: A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) veneto-clax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided ve-netoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-510294-34-00

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
HOVON165: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or Small Lymphocytic Lymphoma. AETHER study (ABT199 + Epcoritamab THErapy for Relapsed/refractory CLL/SLL)
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-500305-40-00  

Sponsor: Regeneron Pharmaceuticals Inc.
OLYMPIA-5: A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-503092-28-00

Rekrutierende Studien

Sponsor: Bristol Myers Squibb
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (MountainTAP-29)
https://clinicaltrials.gov/study/NCT07063745?term=2025-521511-40&viewType=Card&rank=1

Sponsor: GSK Glaxo Smith Kline 
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) GSK 223674
https://clinicaltrials.gov/study/NCT07099898?term=%202025-521627-78%C2%A0&viewType=Card&rank=1

Sponsor: Pfizer
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
https://clinicaltrials.gov/study/NCT07144280?term=2025-521281-97-00&viewType=Card&rank=1

Sponsor Merck Sharp & Dohme LLC
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)V940-009 Interpath.
https://clinicaltrials.gov/study/NCT06623422?cond=NSCLC&term=%20V940-009&intr=%20&rank=1 

Sponsor: Bayer AG
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
(Soho-02)
https://clinicaltrials.gov/study/NCT06452277

Sponsor: Ose Immunotherapeutics
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 vs. Docetaxel in HLA-A2 positive patients with metastatic NSCLC and secondary resistance to Immune Checkpoint Inhibitor (Artemia)
https://clinicaltrials.gov/study/NCT06472245  

Rekrutierung beendet

Sponsor: Bristol Myers Squibb
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)
https://clinicaltrials.gov/study/NCT06646276

Sponsor: Immutep S.A.S.
TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.
https://clinicaltrials.gov/study/NCT06726265?cond=NSCLC&term=%20&intr=eftilagimod&rank=2

Sponsor: TU Dresden
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung
Einarmige Phase II-Studie mit Atezolizumab, Platin und Etoposid zur Behandlung des fortgeschrittenen großzellig-neuroendokrinen Lungenkarzinoms
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002683-31/DE

Sponsor: UK Essen
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/​Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)
https://clinicaltrials.gov/study/NCT04202809?cond=NSCLC&term=espadurva&rank=1

Sponsor: DKFZ
CATCH: Comprehensive Assessment of Clinical Features and Biomarkers to Identify Patients with Advanced or Metastatic Breast Cancer for Marker Driven Trials in Humans
https://clinicaltrials.gov/study/NCT05652569

Sponsor: DKFZ
COGNITION: Comprehensive Assessment of Clinical Features, Genomics and Further Molecular Markers to Identify Patients with Early Breast Cancer for Enrolment on Marker Driven Trials (Molecular Diagnostic Platform)
https://clinicaltrials.gov/study/NCT05906407

Sponsor: Universitätsklinikum Ulm
SURVIVE: Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer – a partially double-blinded, multi-center, randomized, controlled superiority study
https://clinicaltrials.gov/study/NCT05658172
(eingeschränkte Rekrutierung möglich)

Sponsor: GBG Forschungs GmbH
ELEMENT: Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations
https://clinicaltrials.gov/study/NCT06201234

Sponsor: GBG Forschungs GmbH
GBG118-LOBSTER: Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- LOBSTER
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-509292-17-00

Sponsor: Universitaetsklinikum Heidelberg AöR
GMMG-HD9 / DSMM XVIII Trial: A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-507402-13-00

Sponsor: Pfizer Inc.
MagnetisMM-32: A Phase 3, Open-Label Study of Elranatamab Monotherapy Versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma Who Received Prior Anti-CD38 Directed Therapy
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-507871-23-00

Rekrutierung beendet

Sponsor: Böhringer Ingelheim
Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Sponsor: Universität Heidelberg
ACO/ARO/AIO-18.2: Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-518077-34-00

Sponsor: Dr. Falk Pharma GmbH
BUL-5/ESD: Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-507897-42-00

Sponsor: Universität Leipzig
CARP: Cholangiocarcinoma treatment with radiofrequency ablation or photodynamic therapy
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-500107-50-00

Sponsor: Universität Bielefeld
ESORES-Trial: Surgery as needed versus surgery on principle in patients with postneoadjuvant clinical complete tumor response of esophageal cancer
https://drks.de/search/en/trial/DRKS00032613

Rekrutierung beendet

Kolonkarzinom

Sponsor: BioNTec

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT04486378?term=biontech&cond=Colorectal+Cancer&cntry=DE&draw=2&rank=1

Sponsor: Konsortium Sichelzellkrankheit, bestehend aus den Universitätsklinika Berlin (Charité), Frankfurt, Hamburg-Eppendorf, Heidelberg und Ulm
Register Sichelzellkrankheit
Dieses Register wendet sich an alle Patienten ab 18 Jahren mit einer Sichelzellkrankheit

Sponsor:Sanofi-Aventis Recherche & Developpement 
LIBRA - EFC17872: A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease
https://clinicaltrials.gov/study/NCT06975865

Sponsor: Universitätsklinikum Regensburg
T-Haplo for SCD: A phase II stratified trial to assess haploidentical T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor
https://clinicaltrials.gov/study/NCT04201210